Essential Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Essential Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.72K	Sell	815 -6	-0.7%	-$103	﹤0.01%	1209
2026 Q2	$19.9K	Sell	821 -12,207	-94%	-$231K	0.01%	909
2026 Q1	$214K	Sell	13,028 -100	-0.8%	-$1.91K	0.07%	278
2025 Q4	$206K	Buy	13,128 +106	+0.8%	+$1.43K	0.06%	309
2025 Q3	$96.5K	Buy	13,022 +20	+0.2%	+$106	0.03%	439
2025 Q2	$58.6K	Buy	+13,002	New	+$58K	0.02%	439

Other funds holding GLUE

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's GLUE Position: Q3 2026 in Review

Essential Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 0.73% in Q3 2026, selling an estimated $103 and leaving 815 shares worth $9.72K. The position accounts for ﹤0.01% of the portfolio, ranked #1209.

Essential Partners first reported a position in GLUE in Q2 2025 and has held it in 6 quarters since. The position peaked at $214K in Q1 2026. 6 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Essential Partners held 815 shares of Monte Rosa Therapeutics worth $9.72K as of Q3 2026.
Essential Partners sold 6 Monte Rosa Therapeutics shares in Q3 2026, an estimated $103.
Monte Rosa Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1209 holding.
Essential Partners first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Monte Rosa Therapeutics position peaked at $214K in Q1 2026.
6 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.